JAK2 and familial pancreatic carcinoma: Indirubin derivative (IRD) E738, NS-018 and SKLB-850, dual JAK2/SRC inhibitors, have demonstrated inhibitory effects in pancreatic cancer, multiple myeloma and B-cell lymphoma [36–38].